Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
Daiichi Sankyo
Accenture
Mallinckrodt
Deloitte
Merck
Federal Trade Commission
AstraZeneca

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,056,500

« Back to Dashboard

Which drugs does patent 7,056,500 protect, and when does it expire?

Patent 7,056,500 protects MOVANTIK and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 7,056,500
Title:Polymer conjugates of opioid antagonists
Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
Inventor(s): Bentley; Michael David (Huntsville, AL), Roberts; Michael James (Williamsburg, VA), Shen; Xiaoming (Madison, AL), Cheng; Lin (Huntsville, AL)
Assignee: Nektar Therapeutics AL, Corporation (Huntsville, AL)
Application Number:10/274,296
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Delivery;

Drugs Protected by US Patent 7,056,500

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Try a Free Trial
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,056,500

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,617,530 Polymer conjugates of opioid antagonists ➤ Try a Free Trial
7,662,365 Polymer conjugates of opioid antagonists ➤ Try a Free Trial
8,349,307 Polymer conjugates of opioid antagonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,056,500

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002360284 ➤ Try a Free Trial
Canada 2463938 ➤ Try a Free Trial
Cyprus 1117608 ➤ Try a Free Trial
Denmark 1436012 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
UBS
AstraZeneca
Covington
Daiichi Sankyo
Mallinckrodt
US Army
Johnson and Johnson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.